Publications by authors named "H E Sarles"
This study, conducted between 4 October 2013, and 30 November 2018, tested the hypothesis that triple antimicrobial therapy, targeting subspecies (MAP), long considered a putative cause, would favorably affect Crohn's disease. A double-blind multicenter study of adults with active Crohn's disease, (i.e.
View Article and Find Full Text PDFArticle Synopsis
- - Volixibat, an ASBT inhibitor, was tested for its potential to treat non-alcoholic steatohepatitis (NASH) by reducing bile acid reuptake and stimulating bile acid production in a double-blind, phase II study with 197 participants.
- - The study found that volixibat failed to achieve key efficacy endpoints after 48 weeks, leading to its termination; participants on placebo had better outcomes than those receiving volixibat.
- - While there were dose-dependent increases in a bile acid synthesis marker and decreases in cholesterol levels, the treatment was associated with mild to moderate side effects, primarily diarrhea, and did not show significant benefits for liver health.
In this interview for Pancreatology, Professor Henri Sarles shares his life experiences as clinical expert and scientist in pancreatic research. He is a pancreatologist recognized worldwide for his contribution to the understanding of pancreatic diseases. In particular, he led the way in the pancreatitis field with the characterization of pathogenesis of chronic pancreatitis.
View Article and Find Full Text PDF